{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:57:35Z","timestamp":1789721855186,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jpet.2025.103571","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T23:27:01Z","timestamp":1743895621000},"page":"103571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is there a continued need for behavioral pharmacology in the discovery and development of medicines?"],"prefix":"10.1016","volume":"392","author":[{"given":"Jeffrey M.","family":"Witkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-8548","authenticated-orcid":false,"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-7712","authenticated-orcid":false,"given":"Daniel P.","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103571_bib58","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib1","series-title":"Psychopharmacology: The Third Generation of Progress","first-page":"1493","article-title":"Nonpharmacological factors determining the behavioral effects of drugs","author":"Barrett","year":"1987"},{"key":"10.1016\/j.jpet.2025.103571_bib2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/mi.2.8.470","article-title":"The emergence of behavioral pharmacology","volume":"2","author":"Barrett","year":"2002","journal-title":"Mol Interv"},{"key":"10.1016\/j.jpet.2025.103571_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF03392303","article-title":"Peter B. Dews (1922\u20132012)","volume":"36","author":"Barrett","year":"2013","journal-title":"Behav Anal"},{"key":"10.1016\/j.jpet.2025.103571_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/jpet.108.139261","article-title":"Peter B. Dews and pharmacological studies on behavior","volume":"326","author":"Barrett","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103571_bib5","first-page":"119","article-title":"Drug effects on behaviors maintained by different events","volume":"vol 3","author":"Barrett","year":"1981"},{"key":"10.1016\/j.jpet.2025.103571_bib6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0022-3565(25)24321-X","article-title":"Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms","volume":"238","author":"Barrett","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103571_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103528","article-title":"Commentary: behavior as an important determinant of drug action","volume":"392","author":"Barrett","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103571_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpet.2025.103571_bib9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.88","article-title":"Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets","volume":"15","author":"Bespalov","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2025.103571_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.sleep.2018.05.027","article-title":"Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions","volume":"49","author":"Billiard","year":"2018","journal-title":"Sleep Med"},{"key":"10.1016\/j.jpet.2025.103571_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004714-199002000-00025","article-title":"Effects of buspirone in seven schizophrenic subjects","volume":"10","author":"Brody","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00406-023-01561-6","article-title":"mGlu2\/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development","volume":"273","author":"Chaki","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jpet.2025.103571_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pbb.2004.03.014","article-title":"Automated tests for measuring the effects of antidepressants in mice","volume":"78","author":"Crowley","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpet.2025.103571_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neubiorev.2005.03.008","article-title":"Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpet.2025.103571_bib15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/02698811211044684","article-title":"Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment","volume":"35","author":"Dawson","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02245592","article-title":"Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants","volume":"121","author":"Detke","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2025.103571_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3565(25)11525-5","article-title":"Studies on behavior. I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward","volume":"113","author":"Dews","year":"1955","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103571_bib18","series-title":"Schedules of Reinforcement","author":"Ferster","year":"1957"},{"key":"10.1016\/j.jpet.2025.103571_bib19","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/17576180.2024.2437283","article-title":"Transforming drug discovery: the impact of AI and molecular simulation on R&D efficiency","volume":"16","author":"Iwata","year":"2024","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpet.2025.103571_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/syn.890180404","article-title":"In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine","volume":"18","author":"Jordan","year":"1994","journal-title":"Synapse"},{"key":"10.1016\/j.jpet.2025.103571_bib21","first-page":"1","article-title":"Determinants of the specificity of behavioral effects of drugs","volume":"60","author":"Kelleher","year":"1968","journal-title":"Ergeb Physiol"},{"key":"10.1016\/j.jpet.2025.103571_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2125.1996.39016.x","article-title":"The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance","volume":"42","author":"Kerr","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.jpet.2025.103571_bib23","first-page":"E255","article-title":"Ethical considerations regarding animal experimentation","volume":"63","author":"Kiani","year":"2022","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.jpet.2025.103571_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.synbio.2024.08.007","article-title":"Tissue chips as headway model and incitement technology","volume":"10","author":"Modi","year":"2024","journal-title":"Synth Syst Biotechnol"},{"key":"10.1016\/j.jpet.2025.103571_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jeab.253","article-title":"Contributions of Peter B. Dews (1922-2012) to the experimental analysis of behavior: a personal perspective and appreciation","volume":"107","author":"Morse","year":"2017","journal-title":"J Exp Anal Behav"},{"key":"10.1016\/j.jpet.2025.103571_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212233","article-title":"Drug discovery in the age of artificial intelligence: transformative target-based approaches","volume":"25","author":"Patne","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103571_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2022.2111415","article-title":"Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2\/3 receptor antagonism","volume":"17","author":"Pilc","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jpet.2025.103571_bib28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103571_bib29","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/acer.13147","article-title":"Proof-of-concept study to assess the nociceptin receptor antagonist LY 2940094 as a new treatment for alcohol dependence","volume":"40","author":"Post","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jpet.2025.103571_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.157.3.327","article-title":"Validity of clinical trials of antidepressants","volume":"157","author":"Quitkin","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpet.2025.103571_bib31","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1124\/dmd.116.070359","article-title":"Occupancy of nociceptin\/orphanin FQ peptide receptors by the antagonist LY2940094 in rats and healthy human subjects","volume":"44","author":"Raddad","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpet.2025.103571_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.572533","article-title":"Curcumin in depression: potential mechanisms of action and current evidence-a narrative review","volume":"11","author":"Ramaholimihaso","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jpet.2025.103571_bib33","first-page":"149","article-title":"Modafinil, a unique wake-promoting drug: a serendipitous discovery in search of a mechanism of action","volume":"8","author":"Rambert","year":"2007","journal-title":"Comp Med Chem II"},{"key":"10.1016\/j.jpet.2025.103571_bib34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s12010-024-05110-2","article-title":"Decoding drug discovery: exploring A-to-Z in silico methods for beginners","volume":"197","author":"Rasul","year":"2025","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.jpet.2025.103571_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/acer.13052","article-title":"A novel, orally bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol seeking in animal models","volume":"40","author":"Rorick-Kehn","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jpet.2025.103571_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14439","article-title":"A highly bioavailable curcumin formulation ameliorates inflammation cytokines and neurotrophic factors in mice with traumatic brain injury","volume":"103","author":"Sakul","year":"2024","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.jpet.2025.103571_bib38","series-title":"Psychopharmacology: A biochemical and Behavioral Approach","author":"Seiden","year":"1977"},{"key":"10.1016\/j.jpet.2025.103571_bib39","series-title":"The Behavior of Organisms","author":"Skinner","year":"1938"},{"key":"10.1016\/j.jpet.2025.103571_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1124\/jpet.115.228221","article-title":"A novel nociceptin receptor antagonist LY2940094 inhibits excessive feeding behavior in rodents: a possible mechanism for the treatment of binge eating disorder","volume":"356","author":"Statnick","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103571_bib59","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/jm500117r","article-title":"Discovery of a novel series of orally active nociceptin\/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7\u2019-thieno[2,3-c]pyran) scaffold","volume":"57","author":"Toledo","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2025.103571_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105666","article-title":"The need for guidance in antidepressant drug development: revisiting the role of the forced swim test and tail suspension test","volume":"151","author":"Trunnell","year":"2024","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib43","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.drudis.2021.08.003","article-title":"The forced swim test has poor accuracy for identifying novel antidepressants","volume":"26","author":"Trunnell","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jpet.2025.103571_bib44","first-page":"19","article-title":"Animal models of depression: validity and applications","volume":"49","author":"Willner","year":"1995","journal-title":"Adv Biochem Psychopharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002130050456","article-title":"Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation","volume":"134","author":"Willner","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2025.103571_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173858","article-title":"Anxiolytics: origins, drug discovery, and mechanisms","volume":"245","author":"Witkin","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpet.2025.103571_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ddr.430200312","article-title":"Analysis of behavioral effects of drugs","volume":"20","author":"Witkin","year":"1990","journal-title":"Drug Develp Res"},{"key":"10.1016\/j.jpet.2025.103571_bib48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/1871527311312040007","article-title":"Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy","volume":"12","author":"Witkin","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.jpet.2025.103571_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/17512433.2023.2198703","article-title":"Clinical pharmacological innovation in the treatment of depression","volume":"16","author":"Witkin","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103571_bib50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2174\/1871527311312040008","article-title":"Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin","volume":"12","author":"Witkin","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.jpet.2025.103571_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.275","article-title":"Preclinical findings predicting efficacy and side-effect profile of LY 2940094, an antagonist of nociceptin receptors","volume":"4","author":"Witkin","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jpet.2025.103571_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173446","article-title":"Clinical investigations of compounds targeting metabotropic glutamate receptors","volume":"219","author":"Witkin","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpet.2025.103571_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharmthera.2013.10.011","article-title":"The biology of nociceptin\/orphanin FQ (N\/OFQ) related to obesity, stress, anxiety, mood, and drug dependence","volume":"141","author":"Witkin","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpet.2025.103571_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2017.09.002","article-title":"Prediction of human efficacious antidepressant doses using the mouse forced swim test","volume":"161","author":"Yuen","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jpet.2025.103571_bib57","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:31:41Z","timestamp":1762209101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525397843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0022356525397843"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103571","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a continued need for behavioral pharmacology in the discovery and development of medicines?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103571"}}